BR9810423A - Derivados de (imidazol-5-il)metil-2-quinolinona como inibidores da proliferação das células do músculo liso - Google Patents
Derivados de (imidazol-5-il)metil-2-quinolinona como inibidores da proliferação das células do músculo lisoInfo
- Publication number
- BR9810423A BR9810423A BR9810423-3A BR9810423A BR9810423A BR 9810423 A BR9810423 A BR 9810423A BR 9810423 A BR9810423 A BR 9810423A BR 9810423 A BR9810423 A BR 9810423A
- Authority
- BR
- Brazil
- Prior art keywords
- alkyl
- alkyloxy
- hydrogen
- alkyloxycarbonyl
- halo
- Prior art date
Links
- 239000003112 inhibitor Substances 0.000 title abstract 2
- 210000000329 smooth muscle myocyte Anatomy 0.000 title abstract 2
- AVGQUILLCRPWKH-UHFFFAOYSA-N 4-(1h-imidazol-5-yl)-3-methyl-1h-quinolin-2-one Chemical class C12=CC=CC=C2NC(=O)C(C)=C1C1=CN=CN1 AVGQUILLCRPWKH-UHFFFAOYSA-N 0.000 title 1
- 230000004663 cell proliferation Effects 0.000 title 1
- 125000000217 alkyl group Chemical group 0.000 abstract 31
- 125000003545 alkoxy group Chemical group 0.000 abstract 13
- 229910052739 hydrogen Inorganic materials 0.000 abstract 8
- 239000001257 hydrogen Substances 0.000 abstract 8
- 150000002431 hydrogen Chemical group 0.000 abstract 7
- 125000004453 alkoxycarbonyl group Chemical group 0.000 abstract 5
- 125000001475 halogen functional group Chemical group 0.000 abstract 5
- 125000004093 cyano group Chemical group *C#N 0.000 abstract 4
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 abstract 4
- -1 amino, hydroxycarbonyl Chemical group 0.000 abstract 3
- 230000035755 proliferation Effects 0.000 abstract 2
- POYSUXIHCXBJPN-UHFFFAOYSA-N 3-Methyl-quinolin-2-ol Chemical class C1=CC=C2NC(=O)C(C)=CC2=C1 POYSUXIHCXBJPN-UHFFFAOYSA-N 0.000 abstract 1
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 abstract 1
- NINIDFKCEFEMDL-UHFFFAOYSA-N Sulfur Chemical group [S] NINIDFKCEFEMDL-UHFFFAOYSA-N 0.000 abstract 1
- 125000003342 alkenyl group Chemical group 0.000 abstract 1
- 125000004448 alkyl carbonyl group Chemical group 0.000 abstract 1
- 125000005189 alkyl hydroxy group Chemical group 0.000 abstract 1
- 125000004414 alkyl thio group Chemical group 0.000 abstract 1
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical group [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 abstract 1
- 210000004027 cell Anatomy 0.000 abstract 1
- 150000001875 compounds Chemical class 0.000 abstract 1
- 239000003814 drug Substances 0.000 abstract 1
- ORTFAQDWJHRMNX-UHFFFAOYSA-N hydroxidooxidocarbon(.) Chemical group O[C]=O ORTFAQDWJHRMNX-UHFFFAOYSA-N 0.000 abstract 1
- 125000004356 hydroxy functional group Chemical group O* 0.000 abstract 1
- 125000002883 imidazolyl group Chemical group 0.000 abstract 1
- 230000002401 inhibitory effect Effects 0.000 abstract 1
- 238000004519 manufacturing process Methods 0.000 abstract 1
- 229910052760 oxygen Inorganic materials 0.000 abstract 1
- 239000001301 oxygen Substances 0.000 abstract 1
- 125000004076 pyridyl group Chemical group 0.000 abstract 1
- 125000002943 quinolinyl group Chemical group N1=C(C=CC2=CC=CC=C12)* 0.000 abstract 1
- 229910052717 sulfur Chemical group 0.000 abstract 1
- 239000011593 sulfur Chemical group 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/4709—Non-condensed quinolines and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
Landscapes
- Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Medicinal Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Epidemiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Cardiology (AREA)
- Vascular Medicine (AREA)
- Urology & Nephrology (AREA)
- Physical Education & Sports Medicine (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Abstract
Patente de Invenção: <B>"DERIVADOS DE (IMIDAZOL-5-IL)METIL-2-QUINOLINONA COMO INIBIDORES DA PROLIFERAçãO DAS CéLULAS DO MúSCULO LISO"<D>. A invenção compreende o uso de compostos da fórmula (I) em que a linha pontilhada representa uma ligação opcional; X é oxigênio ou enxofre; R¹ é hidrogênio, C~ 1-12~ alquila, Ar¹, Ar² C~ 1-6~ alquila, quinolinil C~ 1-6~ alquila, piridil, C~1-6~ alquila, hidróxi C~ 1-6~ alquila, C~ 1-6~ alquilóxi C~ 1-6~ alquila, mono- ou di(C~1-6~ alquil) amino C~ 1-6~alquila, amino C~ 1-6~ alquila; ou um radical de fórmula -Alk¹-C(=O)-R^ 9^, -Alk¹-S(O)-R^ 9^ ou -Alk¹-S(O~ 2~)-R^ 9^; R², R³ e R^ 16^ são cada um independentemente hidrogênio, hidróxi, halo, ciano, C~ 1-6~ alquila, C~ 1-6~ alquilóxi, hidróxi C~ 1-6~ alquilóxi, C~ 1-6~ alquilóxi C~ 1-6~ alquilóxi, amino C~ 1-6~ alquilóxi, mono- ou di(C~ 1-6~ alquil) amino C~ 1-6~ alquilóxi, Ar¹, Ar² C~ 1-6~ alquila, Ar²óxi, Ar² C~ 1-6~ alquilóxi, hidroxicarbonila, C~ 1-6~ alquiloxicarbonila, trialometila, trialometóxi, C~ 2-6~ alquenila; R^ 4^ e R^ 5^ são cada um independentemente hidrogênio, halo, Ar¹, C~ 1-6~ alquila, hidróxi C~ 1-6~ alquila, C~ 1-6~ alquilóxi C~ 1-6~ alquila, C~ 1-6~ alquiolóxi, C~ 1-6~ alquiltio, amino, hidroxicarbonila, C~ 1-6~ alquiloxicarbonila, C~ 1-6~ alquil S(O) C~ 1-6~ alquila ou C~ 1-6~ alquil S(O)~ 2~ C~ 1-6~ alquila; R^ 6^ e R^ 7^ são cada um independetemente hidrogênio, halo, ciano, C~ 1-6~ alquila, 4,4-dimetiloxazolila C~ 1-6~ alquilóxi, ou Ar²óxi; R^ 8^ é hidrogênio, C~ 1-6~ alquila, ciano, hidroxicarbonila, C~ 1-6~ alquiloxicarbonila, C~ 1-6~ alquilcarbonil C~ 1-6~ alquila, ciano C~ 1-6~ alquila, C~ 1-6~ alquiloxicarbonil C~ 1-6~ alquila, carbóxi C~ 1-6~ alquila, hidróxi C~ 1-6~ alquila, amino C~ 1-6~ alquila, mono- ou di(C~ 1-6~ alquil) amino C~ 1-6~ alquila, imidazolila, halo C~ 1-6~ alquila, C~ 1-6~ alquilóxi C~ 1-6~ alquila, aminocarbonil C~ 1-6~ alquila ou um radical de fórmula -O-R^ 10^, -S-R^ 10^, N-R^ 11^O^ 12^; R^ 17^ é hidrogênio, halo, ciano, C~ 1-6~ alquila, C~ 1-6~ alquiloxicarbonila, Ar¹; R^ 18^ é hidrogênio, C~ 1-6~ alquila, C~ 1-6~ alquilóxi ou halo; R^ 19^ é hidrogênio ou C~ 1-6~ alquila; para a fabricação de um medicamento para a inibição da proliferação das células do músculo liso.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US4737697P | 1997-06-02 | 1997-06-02 | |
| PCT/EP1998/003182 WO1998055124A1 (en) | 1997-06-02 | 1998-05-25 | (imidazol-5-yl)methyl-2-quinolinone derivatives as inhibitors of smooth muscle cell proliferation |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| BR9810423A true BR9810423A (pt) | 2000-10-03 |
Family
ID=21948611
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| BR9810423-3A BR9810423A (pt) | 1997-06-02 | 1998-05-25 | Derivados de (imidazol-5-il)metil-2-quinolinona como inibidores da proliferação das células do músculo liso |
Country Status (22)
| Country | Link |
|---|---|
| US (4) | US6365600B1 (pt) |
| EP (1) | EP0988038B1 (pt) |
| JP (1) | JP4209472B2 (pt) |
| KR (1) | KR100517832B1 (pt) |
| CN (2) | CN1231215C (pt) |
| AT (1) | ATE222104T1 (pt) |
| AU (1) | AU740603B2 (pt) |
| BR (1) | BR9810423A (pt) |
| CA (1) | CA2290992C (pt) |
| DE (1) | DE69807222T2 (pt) |
| DK (1) | DK0988038T3 (pt) |
| ES (1) | ES2182327T3 (pt) |
| HK (2) | HK1025046A1 (pt) |
| ID (1) | ID24675A (pt) |
| IL (1) | IL133212A (pt) |
| NO (1) | NO318834B1 (pt) |
| NZ (1) | NZ501401A (pt) |
| PT (1) | PT988038E (pt) |
| RU (1) | RU2209066C2 (pt) |
| TR (1) | TR199902923T2 (pt) |
| WO (1) | WO1998055124A1 (pt) |
| ZA (1) | ZA984700B (pt) |
Families Citing this family (100)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| ATE222104T1 (de) | 1997-06-02 | 2002-08-15 | Janssen Pharmaceutica Nv | (imidazol-5-yl)methyl-2-quinolinone derivativen als inhibitoren von proliferation der glatten muskelzellen |
| US20030040790A1 (en) * | 1998-04-15 | 2003-02-27 | Furst Joseph G. | Stent coating |
| US20020099438A1 (en) * | 1998-04-15 | 2002-07-25 | Furst Joseph G. | Irradiated stent coating |
| TR200003882T2 (tr) * | 1998-07-06 | 2001-06-21 | Janssen Pharmaceutica N.V. | Artropatilerin tedavisi için farnesil protein transferaz inhibitörleri. |
| US8070796B2 (en) | 1998-07-27 | 2011-12-06 | Icon Interventional Systems, Inc. | Thrombosis inhibiting graft |
| US7967855B2 (en) | 1998-07-27 | 2011-06-28 | Icon Interventional Systems, Inc. | Coated medical device |
| ES2237125T3 (es) * | 1998-08-27 | 2005-07-16 | Pfizer Products Inc. | Derivados de quinolin-2-ona utiles como agentes anticancerigenos. |
| PT1140935E (pt) * | 1998-12-23 | 2003-10-31 | Janssen Pharmaceutica Nv | Derivados da quinolina 1,2-ciclizada |
| CZ20012910A3 (cs) | 1999-02-11 | 2002-02-13 | Pfizer Products Inc. | Heteroarylem-substituované chinolin-2-onové deriváty pouľitelné jako protinádorové prostředky |
| ES2212971T3 (es) * | 1999-11-30 | 2004-08-16 | Pfizer Products Inc. | Derivados de quinolina utiles para la inhibicion de la farnesil protein transferasa. |
| US6844357B2 (en) * | 2000-05-01 | 2005-01-18 | Pfizer Inc. | Substituted quinolin-2-one derivatives useful as antiproliferative agents |
| JO2361B1 (en) | 2000-06-22 | 2006-12-12 | جانسين فارماسيوتيكا ان. في | Enaniumer 1,2-anylated quinoline inhibitor for the transporter - farnesyl |
| CZ304344B6 (cs) | 2000-09-11 | 2014-03-19 | Novartis Vaccines & Diagnostics, Inc. | Chinolinonový derivát a jeho použití a farmaceutický prostředek s obsahem tohoto derivátu |
| FR2813791B1 (fr) * | 2000-09-14 | 2004-03-12 | Lafon Labor | Utilisation de 2- et 4-quinolones pour inhiber la neo-proliferation intimale |
| AU2001293826A1 (en) | 2000-09-25 | 2002-04-02 | Janssen Pharmaceutica N.V. | Farnesyl transferase inhibiting quinoline and quinazoline derivatives as farnesyl transferase inhibitors |
| JP4974439B2 (ja) | 2000-09-25 | 2012-07-11 | ジヤンセン・フアーマシユーチカ・ナームローゼ・フエンノートシヤツプ | ファルネシルトランスフェラーゼを阻害する６−ヘテロシクリルメチルキノリノン誘導体 |
| WO2002024683A1 (en) * | 2000-09-25 | 2002-03-28 | Janssen Pharmaceutica N.V. | Farnesyl transferase inhibiting 6-[(substituted phenyl)methyl]-quinoline and quinazoline derivatives |
| WO2002024686A2 (en) | 2000-09-25 | 2002-03-28 | Janssen Pharmaceutica N.V. | Farnesyl transferase inhibiting 6-heterocyclylmethyl quinoline and quinazoline derivatives |
| ATE434615T1 (de) | 2000-11-21 | 2009-07-15 | Janssen Pharmaceutica Nv | Farnesyltransferase hemmende benzoheterocyclische derivate |
| ES2260316T3 (es) | 2000-12-27 | 2006-11-01 | Janssen Pharmaceutica N.V. | Derivados de quinazolina y quinolina 4-sustituidos que inhiben la farnesil transferasa. |
| WO2003000266A1 (en) | 2001-06-21 | 2003-01-03 | Ariad Pharmaceuticals, Inc. | Novel quinolines and uses thereof |
| EP1458720B1 (en) | 2001-12-19 | 2009-03-18 | Janssen Pharmaceutica N.V. | 1,8-annelated quinoline derivatives substituted with carbon-linked triazoles as farnesyl transferase inhibitors |
| US7354932B2 (en) | 2001-12-21 | 2008-04-08 | Anormed, Inc. | Chemokine receptor binding heterocyclic compounds with enhanced efficacy |
| WO2003080058A1 (en) | 2002-03-22 | 2003-10-02 | Janssen Pharmaceutica. N.V. | Benzylimidazolyl substituted 2-quinoline and quinazoline derivatives for use as farnesyl transferase inhibitors |
| ES2271574T3 (es) | 2002-04-15 | 2007-04-16 | Janssen Pharmaceutica N.V. | Derivados triciclicos de quinazolina inhibidores de la farnesiltransferasa, sustituidos con imidazoles o triazoles enlazados al carbono. |
| US8016881B2 (en) | 2002-07-31 | 2011-09-13 | Icon Interventional Systems, Inc. | Sutures and surgical staples for anastamoses, wound closures, and surgical closures |
| US7825132B2 (en) | 2002-08-23 | 2010-11-02 | Novartis Vaccines And Diagnostics, Inc. | Inhibition of FGFR3 and treatment of multiple myeloma |
| US6638301B1 (en) * | 2002-10-02 | 2003-10-28 | Scimed Life Systems, Inc. | Medical device with radiopacity |
| JP2006511616A (ja) | 2002-11-13 | 2006-04-06 | カイロン コーポレイション | 癌の処置方法およびその関連方法 |
| US20050154451A1 (en) * | 2003-12-18 | 2005-07-14 | Medtronic Vascular, Inc. | Medical devices to treat or inhibit restenosis |
| US7211108B2 (en) * | 2004-01-23 | 2007-05-01 | Icon Medical Corp. | Vascular grafts with amphiphilic block copolymer coatings |
| NZ547277A (en) * | 2004-01-23 | 2009-08-28 | Janssen Pharmaceutica Nv | Substituted quinolines and their use as mycobacterial inhibitors |
| RU2377988C2 (ru) | 2004-02-20 | 2010-01-10 | Новартис Вэксинес Энд Дайэгностикс, Инк. | Модуляция воспалительных и метастатических процессов |
| ES2614508T3 (es) * | 2004-03-15 | 2017-05-31 | Genzyme Corporation | Proceso para la síntesis de un antagonista de CXCR4 |
| US20050277629A1 (en) * | 2004-03-18 | 2005-12-15 | The Brigham And Women's Hospital, Inc. | Methods for the treatment of synucleinopathies (Lansbury) |
| US20050272722A1 (en) * | 2004-03-18 | 2005-12-08 | The Brigham And Women's Hospital, Inc. | Methods for the treatment of synucleinopathies |
| EP1732549A4 (en) * | 2004-03-18 | 2009-11-11 | Brigham & Womens Hospital | METHOD FOR THE TREATMENT OF SYNUCLEINOPATHIES |
| CA2559221A1 (en) * | 2004-03-18 | 2005-09-29 | Brigham And Women's Hospital, Inc. | Methods for the treatment of synucleinopathies |
| WO2005089518A2 (en) * | 2004-03-18 | 2005-09-29 | The Brigham And Women's Hospital, Inc. | Uch-l1 expression and cancer therapy |
| US20070293539A1 (en) * | 2004-03-18 | 2007-12-20 | Lansbury Peter T | Methods for the treatment of synucleinopathies |
| US7063720B2 (en) * | 2004-09-14 | 2006-06-20 | The Wallace Enterprises, Inc. | Covered stent with controlled therapeutic agent diffusion |
| US20060083770A1 (en) * | 2004-10-15 | 2006-04-20 | Specialty Coating Systems, Inc. | Medical devices and methods of preparation and use |
| US20060194821A1 (en) * | 2005-02-18 | 2006-08-31 | The Brigham And Women's Hospital, Inc. | Compounds inhibiting the aggregation of superoxide dismutase-1 |
| US8323333B2 (en) * | 2005-03-03 | 2012-12-04 | Icon Medical Corp. | Fragile structure protective coating |
| US20060201601A1 (en) * | 2005-03-03 | 2006-09-14 | Icon Interventional Systems, Inc. | Flexible markers |
| US7540995B2 (en) | 2005-03-03 | 2009-06-02 | Icon Medical Corp. | Process for forming an improved metal alloy stent |
| US20060200048A1 (en) * | 2005-03-03 | 2006-09-07 | Icon Medical Corp. | Removable sheath for device protection |
| WO2006110197A2 (en) | 2005-03-03 | 2006-10-19 | Icon Medical Corp. | Polymer biodegradable medical device |
| US20060264914A1 (en) * | 2005-03-03 | 2006-11-23 | Icon Medical Corp. | Metal alloys for medical devices |
| US9107899B2 (en) | 2005-03-03 | 2015-08-18 | Icon Medical Corporation | Metal alloys for medical devices |
| BRPI0611375A2 (pt) | 2005-05-23 | 2010-08-31 | Novartis Ag | formas cristalinas e outras de sais de ácido láctico de 4-amino-5-flúor-3-[6-(4-metilpiperazin-1-il)-1h-benzimid azol-2-il]-1h-quinolin-2-ona |
| AU2006275514B2 (en) | 2005-07-29 | 2012-04-05 | Resverlogix Corp. | Pharmaceutical compositions for the prevention and treatment of complex diseases and their delivery by insertable medical devices |
| EP2545919A1 (en) | 2005-12-23 | 2013-01-16 | Link Medicine Corporation | Treatment of synucleinopathies |
| US20070148390A1 (en) * | 2005-12-27 | 2007-06-28 | Specialty Coating Systems, Inc. | Fluorinated coatings |
| JP5498168B2 (ja) * | 2006-12-01 | 2014-05-21 | ブリストル−マイヤーズ スクイブ カンパニー | アテローム性動脈硬化および循環器疾患の治療のためのｃｅｔｐ阻害剤としてのｎ−（（３−ベンジル）−２，２−（ビス−フェニル）−プロパン−１−アミン誘導体 |
| PT2118074E (pt) | 2007-02-01 | 2014-03-20 | Resverlogix Corp | Compostos para a prevenção e tratamento de doenças cardiovasculares |
| AU2008256928A1 (en) * | 2007-05-23 | 2008-12-04 | Allergan, Inc. | Therapeutic ((phenyl)imidazolyl)methylquinolinyl compounds |
| US8232402B2 (en) * | 2008-03-12 | 2012-07-31 | Link Medicine Corporation | Quinolinone farnesyl transferase inhibitors for the treatment of synucleinopathies and other indications |
| CA2711103C (en) | 2008-06-26 | 2016-08-09 | Resverlogix Corp. | Methods of preparing quinazolinone derivatives |
| WO2010057006A1 (en) * | 2008-11-13 | 2010-05-20 | Link Medicine Corporation | Azaquinolinone derivatives and uses thereof |
| US20110060005A1 (en) * | 2008-11-13 | 2011-03-10 | Link Medicine Corporation | Treatment of mitochondrial disorders using a farnesyl transferase inhibitor |
| US20100331363A1 (en) * | 2008-11-13 | 2010-12-30 | Link Medicine Corporation | Treatment of mitochondrial disorders using a farnesyl transferase inhibitor |
| CA2747417C (en) | 2009-01-08 | 2017-01-03 | Resverlogix Corp. | Compounds for the prevention and treatment of cardiovascular disease |
| CA3146333A1 (en) | 2009-03-18 | 2010-09-23 | Resverlogix Corp. | Phenyl-quinazolin-4(3h)-one and phenyl-pyrido[2,3-d]pyrimidin-4(3h)-one derivatives and compositions thereof useful as anti-inflammatory agents |
| LT2421533T (lt) | 2009-04-22 | 2018-12-27 | Resverlogix Corp. | Nauji priešuždegiminiai agentai |
| US8398916B2 (en) | 2010-03-04 | 2013-03-19 | Icon Medical Corp. | Method for forming a tubular medical device |
| JP5992049B2 (ja) | 2011-11-01 | 2016-09-14 | レスバーロジックス コーポレイション | 置換されたキナゾリノンのための経口速放性製剤 |
| CN104093709B (zh) * | 2012-02-13 | 2017-09-22 | 霍夫曼-拉罗奇有限公司 | 作为醛固酮合酶抑制剂的咪唑基酮衍生物 |
| EP2909189B8 (en) | 2012-10-16 | 2017-04-19 | Janssen Pharmaceutica NV | Heteroaryl linked quinolinyl modulators of ror-gamma-t |
| WO2014062658A1 (en) * | 2012-10-16 | 2014-04-24 | Janssen Pharmaceutica Nv | Methylene linked quinolinyl modulators of ror-gamma-t |
| CN105073729A (zh) * | 2012-10-16 | 2015-11-18 | 詹森药业有限公司 | RORγt的苯基连接的喹啉基调节剂 |
| US9073878B2 (en) | 2012-11-21 | 2015-07-07 | Zenith Epigenetics Corp. | Cyclic amines as bromodomain inhibitors |
| WO2014080291A2 (en) | 2012-11-21 | 2014-05-30 | Rvx Therapeutics Inc. | Biaryl derivatives as bromodomain inhibitors |
| AU2013365926B9 (en) | 2012-12-21 | 2019-01-17 | Zenith Epigenetics Ltd. | Novel heterocyclic compounds as bromodomain inhibitors |
| US9328095B2 (en) | 2013-10-15 | 2016-05-03 | Janssen Pharmaceutica Nv | Heteroaryl linked quinolinyl modulators of RORgammat |
| US9284308B2 (en) | 2013-10-15 | 2016-03-15 | Janssen Pharmaceutica Nv | Methylene linked quinolinyl modulators of RORγt |
| US9221804B2 (en) | 2013-10-15 | 2015-12-29 | Janssen Pharmaceutica Nv | Secondary alcohol quinolinyl modulators of RORγt |
| US9403816B2 (en) | 2013-10-15 | 2016-08-02 | Janssen Pharmaceutica Nv | Phenyl linked quinolinyl modulators of RORγt |
| US10555941B2 (en) | 2013-10-15 | 2020-02-11 | Janssen Pharmaceutica Nv | Alkyl linked quinolinyl modulators of RORγt |
| WO2015057626A1 (en) | 2013-10-15 | 2015-04-23 | Janssen Pharmaceutica Nv | QUINOLINYL MODULATORS OF RORyT |
| US9346782B2 (en) | 2013-10-15 | 2016-05-24 | Janssen Pharmaceutica Nv | Alkyl linked quinolinyl modulators of RORγt |
| US10076512B2 (en) | 2014-05-01 | 2018-09-18 | Eiger Biopharmaceuticals, Inc. | Treatment of hepatitis delta virus infection |
| US11311519B2 (en) | 2014-05-01 | 2022-04-26 | Eiger Biopharmaceuticals, Inc. | Treatment of hepatitis delta virus infection |
| EP3160397A4 (en) | 2014-06-24 | 2018-03-21 | Icon Medical Corp. | Improved metal alloys for medical devices |
| US20210322651A1 (en) * | 2014-12-18 | 2021-10-21 | Senex Biotechnology, Inc. | Suppression of neointimal formation following vascular surgeru using cdk8 inhibitors |
| WO2016147053A1 (en) | 2015-03-13 | 2016-09-22 | Resverlogix Corp. | Compositions and therapeutic methods for the treatment of complement-associated diseases |
| CN107530338B (zh) | 2015-04-21 | 2020-12-01 | 艾格尔峰生物制药有限公司 | 包含洛那法尼和利托那韦的药物组合物 |
| PT3385395T (pt) | 2015-08-17 | 2020-05-06 | Kura Oncology Inc | Métodos de tratamento de doentes com cancro usando inibidores da farnesiltransferase |
| WO2017106328A1 (en) | 2015-12-14 | 2017-06-22 | X4 Pharmaceuticals, Inc. | Methods for treating cancer |
| US11357742B2 (en) | 2015-12-14 | 2022-06-14 | X4 Pharmaceuticals, Inc. | Methods for treating cancer |
| US10610527B2 (en) | 2015-12-22 | 2020-04-07 | X4 Pharmaceuticals, Inc. | Methods for treating immunodeficiency disease |
| US11766506B2 (en) | 2016-03-04 | 2023-09-26 | Mirus Llc | Stent device for spinal fusion |
| JP2019510785A (ja) | 2016-04-08 | 2019-04-18 | エックス４ ファーマシューティカルズ， インコーポレイテッド | 癌を処置する方法 |
| CA3027495A1 (en) | 2016-06-21 | 2017-12-28 | X4 Pharmaceuticals, Inc. | Cxcr4 inhibitors and uses thereof |
| EP3472129A4 (en) | 2016-06-21 | 2019-12-04 | X4 Pharmaceuticals, Inc. | CXCR4 INHIBITORS AND USES THEREOF |
| CN109562106B (zh) | 2016-06-21 | 2023-03-21 | X4 制药有限公司 | Cxcr4抑制剂及其用途 |
| MX2019005065A (es) | 2016-11-03 | 2019-08-21 | Kura Oncology Inc | Metodos de tratamiento de pacientes con cancer con inhibidores de farnesiltransferasa. |
| US10548889B1 (en) | 2018-08-31 | 2020-02-04 | X4 Pharmaceuticals, Inc. | Compositions of CXCR4 inhibitors and methods of preparation and use |
| CN110204487B (zh) * | 2019-06-21 | 2021-09-28 | 江南大学 | 一种喹啉衍生物的合成方法 |
| CN113072490B (zh) * | 2021-03-26 | 2022-08-16 | 中国海洋大学 | 一种替吡法尼喹啉酮中间体的高效合成方法 |
Family Cites Families (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| SE456347B (sv) | 1982-02-09 | 1988-09-26 | Ird Biomaterial Ab | Ytmodifierat fast substrat samt forfarande for framstellning derav |
| US5213898A (en) | 1989-10-12 | 1993-05-25 | Norsk Hydro A.S. | Process for the preparation of surface modified solid substrates |
| US5049403A (en) | 1989-10-12 | 1991-09-17 | Horsk Hydro A.S. | Process for the preparation of surface modified solid substrates |
| US5356433A (en) | 1991-08-13 | 1994-10-18 | Cordis Corporation | Biocompatible metal surfaces |
| JPH07112930A (ja) * | 1993-10-14 | 1995-05-02 | Kyowa Hakko Kogyo Co Ltd | 血管平滑筋細胞増殖抑制剤 |
| EP0822788B1 (en) | 1995-04-19 | 2002-09-04 | Schneider (Usa) Inc. | Drug release coated stent |
| US5607475A (en) | 1995-08-22 | 1997-03-04 | Medtronic, Inc. | Biocompatible medical article and method |
| US5863904A (en) | 1995-09-26 | 1999-01-26 | The University Of Michigan | Methods for treating cancers and restenosis with P21 |
| TW349948B (en) * | 1995-10-31 | 1999-01-11 | Janssen Pharmaceutica Nv | Farnesyl transferase inhibiting 2-quinolone derivatives |
| TR199800825T2 (xx) * | 1995-12-08 | 1998-08-21 | Janssen Pharmaceutica N.V. | Farnesil protein transferini inhibe eden (imidazol-5-il) metil-2-kinolinon t�revleri. |
| ATE222104T1 (de) | 1997-06-02 | 2002-08-15 | Janssen Pharmaceutica Nv | (imidazol-5-yl)methyl-2-quinolinone derivativen als inhibitoren von proliferation der glatten muskelzellen |
-
1998
- 1998-05-25 AT AT98928332T patent/ATE222104T1/de active
- 1998-05-25 BR BR9810423-3A patent/BR9810423A/pt not_active Application Discontinuation
- 1998-05-25 PT PT98928332T patent/PT988038E/pt unknown
- 1998-05-25 TR TR1999/02923T patent/TR199902923T2/xx unknown
- 1998-05-25 CN CNB98805700XA patent/CN1231215C/zh not_active Expired - Lifetime
- 1998-05-25 ES ES98928332T patent/ES2182327T3/es not_active Expired - Lifetime
- 1998-05-25 AU AU80207/98A patent/AU740603B2/en not_active Expired
- 1998-05-25 CA CA002290992A patent/CA2290992C/en not_active Expired - Lifetime
- 1998-05-25 DK DK98928332T patent/DK0988038T3/da active
- 1998-05-25 KR KR10-1999-7010744A patent/KR100517832B1/ko not_active IP Right Cessation
- 1998-05-25 WO PCT/EP1998/003182 patent/WO1998055124A1/en active IP Right Grant
- 1998-05-25 IL IL13321298A patent/IL133212A/en not_active IP Right Cessation
- 1998-05-25 DE DE69807222T patent/DE69807222T2/de not_active Expired - Lifetime
- 1998-05-25 RU RU2000100032/14A patent/RU2209066C2/ru active
- 1998-05-25 CN CNB2005101163581A patent/CN100525766C/zh not_active Expired - Lifetime
- 1998-05-25 JP JP50144099A patent/JP4209472B2/ja not_active Expired - Lifetime
- 1998-05-25 EP EP98928332A patent/EP0988038B1/en not_active Expired - Lifetime
- 1998-05-25 NZ NZ501401A patent/NZ501401A/en not_active IP Right Cessation
- 1998-05-28 ID IDW991506A patent/ID24675A/id unknown
- 1998-06-01 ZA ZA9804700A patent/ZA984700B/xx unknown
-
1999
- 1999-05-25 US US09/445,009 patent/US6365600B1/en not_active Expired - Lifetime
- 1999-12-01 NO NO19995883A patent/NO318834B1/no not_active IP Right Cessation
-
2000
- 2000-07-08 HK HK00104198A patent/HK1025046A1/xx not_active IP Right Cessation
-
2001
- 2001-11-28 US US09/996,147 patent/US6743805B2/en not_active Expired - Lifetime
-
2003
- 2003-06-18 US US10/464,570 patent/US6734194B2/en not_active Expired - Lifetime
-
2004
- 2004-04-14 US US10/823,862 patent/US7253183B2/en not_active Expired - Lifetime
-
2006
- 2006-08-16 HK HK06109112.8A patent/HK1088820A1/xx not_active IP Right Cessation
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| BR9810423A (pt) | Derivados de (imidazol-5-il)metil-2-quinolinona como inibidores da proliferação das células do músculo liso | |
| BR9913745A (pt) | Cetonas de piridina úteis como herbicidas | |
| CY1107214T1 (el) | Αγωνιστες και ανταγωνιστες υποδοχεων λυσοφωσφατιδικου οξεος (lpa) kai τροποι χρησης | |
| BR0012984A (pt) | Método para tratar um estado associado com o mc4-r em um mamìfero, composto de ligação ao mc4-r, e, composição farmacêutica | |
| BR9916282A (pt) | Composto, uso de um um composto e método de tratamento | |
| TR199801255T2 (xx) | Vitronektin resept�r antagonistleri. | |
| TR199701574T2 (xx) | �midazol bile�imleri | |
| PT1246809E (pt) | Compostos de 5-aril-1h-1,2,4-triazole como inibidores de ciclooxigenase-2 e composicoes farmaceuticas que os contem | |
| IL112495A0 (en) | Phenylacetic acid derivatives, their preparation and compositions containing them | |
| TR200002480T2 (tr) | İzaşemi tedavisi için guanidin türevleri | |
| DE69801048T2 (de) | Fungizide trifluorophenyl-triazolopyrimidine | |
| TR200102025T2 (tr) | Dopamin-D3-Reseptör afinitesine sahip triazol bileşikleri | |
| NZ506329A (en) | Inhibitors of phospholipase enzymes | |
| AR024138A1 (es) | Inhibidores de la proliferacion celular | |
| BR9811948A (pt) | Secretores de hormÈnio do crescimento | |
| IT1285770B1 (it) | Composti corticoidei | |
| BR9713338A (pt) | Benzonaftiridinas como terapêuticos brÈnquicos. | |
| AR029838A1 (es) | Heterociclos benzonitrogenados sustituidos | |
| BR9907847A (pt) | Agentes anti-inflamatórios seletivos para glucocorticóides | |
| EE9900551A (et) | Tsüanoguanidiinid kui rakkude paljunemise inhibiitorid | |
| MX9302034A (es) | Bencidazoles, medicamentos que contienen estos compuestos y procedimientos para su preparacion. | |
| AR004780A1 (es) | Derivados de 2-tioxo-imidazolidin-4-ona | |
| ATE248819T1 (de) | Cyanoguanidine als zellproliferation inhibitoren | |
| BR9912307A (pt) | Inibidores fkbp | |
| AR009452A1 (es) | Compuestos de dihalopropeno, los agentes insecticidas/acaricidas que los contienen y los intermediarios de sintesis de dichos compuestos. |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| B07A | Application suspended after technical examination (opinion) [chapter 7.1 patent gazette] | ||
| B15K | Others concerning applications: alteration of classification |
Free format text: ALTERADA DE INT:CL.8: A61K 31/4709, A61P 9/10 Ipc: A61K 31/4709 (2007.10), A61P 9/10 (2007.10) |
|
| B06A | Patent application procedure suspended [chapter 6.1 patent gazette] | ||
| B07A | Application suspended after technical examination (opinion) [chapter 7.1 patent gazette] | ||
| B09B | Patent application refused [chapter 9.2 patent gazette] |
Free format text: INDEFERIDO O PEDIDO COM BASE NO ARTIGO 24 DA LPI. |
|
| B12B | Appeal against refusal [chapter 12.2 patent gazette] |